Clinical trials of the anti-HER2 mAb trastuzumab alone or in combination with chemotherapy have shown negative results in HER2 OE NSCLC, while some activity has been observed in HER2 AMP NSCLC (Table 1) [53,54,55,56,57,58,59,60,61]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.